NCT01021436 - Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Pneumonia

Interventions

DRUG

Amikacin inhalation solution (BAY41-6551)

Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour

Trial Locations (6)

Birminghan

Memphis

Cincinnati

Paris

Houston

Limoges